Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Adjusted earnings of $2.17 a share topped the $2.02 analysts were anticipating, according to FactSet. However, second-quarter ...

Pharmaceutical heavyweights Merck & Co. Inc. (NYSE: MRK) and Eli Lilly and Company (NYSE: LLY) are getting a lot of attention after outperforming the market by a mile in 2018.

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) are both among the largest biopharmaceutical businesses in the world, but their growth prospects aren't exactly the same. Nonetheless, the pair handily ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

Merck’s stock has declined by close to 10% since early February after the WHO declared the coronavirus a global health emergency, while Eli Lilly stock has fared much better and gained 15%. The ...

Looking at financial risk, Merck’s 14.3% debt as a percentage of equity is higher than 5.7% for Eli Lilly, while its 9.7% cash as a percentage of assets is higher than 5.8% for the latter ...

Sales of Covid-19 drugs fueled year-over-year revenue growth for Merck MRK 0.13% & Co. Inc. and Eli Lilly LLY -2.71% & Co. in the last three months of 2021, underscoring the pandemic response’s ...

Pharmaceutical heavyweights Merck & Co. Inc. (MRK -0.26%) and Eli Lilly and Company (LLY 3.78%) are getting a lot of attention after outperforming the market by a mile in 2018.